Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAX (Gemcitabine, Abraxane, Xeloda) in Metastatic Pancreatic Cancer
NCT02581501Phase 1Withdrawn
- Sponsor
- Stamford Hospital
- Start
- Feb 2016
- Primary completion
- Dec 2016
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of nab-paclitaxel, gemcitabine and capecitabine in pancreatic cancer (PC) (4 arms), sponsored by Stamford Hospital. Primary endpoint: Maximum Tolerated Dose and Dose Intensity at 24 months. Planned start Feb 2016; status: withdrawn.
02
Drugs
nab-paclitaxelgemcitabinecapecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02581501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581501.